Statements (22)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
gptkb:Ipsen
|
| gptkbp:acquisitionYear |
2022
|
| gptkbp:CEO |
Robert Bazemore
|
| gptkbp:focus |
epigenetic therapies
|
| gptkbp:founded |
2007
|
| gptkbp:founder |
gptkb:Jean-Philippe_Vert
gptkb:Yang_Shi Robert A. Copeland |
| gptkbp:headquartersLocation |
gptkb:Cambridge,_Massachusetts,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Epizyme, Inc.
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:notableProduct |
gptkb:Tazverik
|
| gptkbp:status |
acquired
|
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
gptkb:EPZM
|
| gptkbp:TazverikIndication |
epithelioid sarcoma
follicular lymphoma |
| gptkbp:website |
https://www.epizyme.com/
|
| gptkbp:bfsParent |
gptkb:EPZ-6438
gptkb:tazemetostat |
| gptkbp:bfsLayer |
8
|